CADTH | Evidence Driven
CADTH | Evidence Driven

lisocabtagene maraleucel

Details

Generic Name:
lisocabtagene maraleucel
Project Status:
Pending
Therapeutic Area:
Relapsed or refractory large B-cell lymphoma
Manufacturer:
Bristol Myers Squibb Canada
Call for patient/clinician input open:
Brand Name:
Breyanzi
Project Line:
Reimbursement Review
Project Number:
PG0358-000
Call for patient/clinician input closed:
Tumour Type:
Lymphoma
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​Breyanzi (lisocabtagene maraleucel) is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma, who are refractory or have relapsed within 12 months of initial therapy and are candidates for autologous haematopoietic stem cell transplant (HSCT).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Breyanzi (lisocabtagene maraleucel) is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma, who are refractory or have relapsed within 12 months of initial therapy and are candidates for autologous haematopoietic stem cell transplant (HSCT).​
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : March 26, 2024